N-acetylglucosaminyltransferase V confers hepatoma cells with resistance to anoikis through EGFR/PAK1 activation

Glycobiology

Volumn 23, Issue 9, 2013, Pages 1097-1109

  Liu, Jing ^a,b,d   Liu, Haiou ^a,b   Zhang, Weijuan ^c   Wu, Qian ^a,b   Liu, Weisi ^a,b   Liu, Yidong ^a,b   Pan, Deng ^a,b   Xu, Jiejie ^a,b   Gu, Jianxin ^a,b  

^a Department of Biochemistry and Molecular Biology ^*  (China)

^b Key Laboratory of Parasite and Vector Biology MOH   (China)

^c FUDAN UNIVERSITY   (China)

^d NANTONG MEDICAL COLLEGE   (China)

Author keywords

Anoikis; EGFR; HCC; Mgat5; PAK1

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALPHA 1,3(6) MANNOSYLGLYCOPROTEIN BETA 1,6 N ACETYLGLUCOSAMINYLTRANSFERASE; CASPASE 3; CASPASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MUTANT PROTEIN; N ACETYLGLUCOSAMINYLTRANSFERASE; P21 ACTIVATED KINASE 1; SHORT HAIRPIN RNA; SWAINSONINE; TUNICAMYCIN; UNCLASSIFIED DRUG;

ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL ANCHORAGE; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GLYCOSYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANOIKIS; EGFR; HCC; MGAT5; PAK1;

ANOIKIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; HEP G2 CELLS; HUMANS; N-ACETYLGLUCOSAMINYLTRANSFERASES; P21-ACTIVATED KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84880964284     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt049     Document Type: Article

References (39)

1. Bishayee S. 2000. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function. Biochem Pharmacol. 60: 1217-1223.
2. Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. 2009. Alteration of protein glycosylation in liver diseases. J Hepatol. 50: 592-603.
3. Chen S, Yin X, Zhu X, Yan J, Ji S, Chen C, Cai M, Zhang S, Zong H, Hu Y, et al. 2003. The C-terminal kinase domain of the p34cdc2-related PITSLRE protein kinase (p110C) associates with p21-activated kinase 1 and inhibits its activity during anoikis. J Biol Chem. 278: 20029-20036.
4. Cheng C, Kong X, Wang H, Gan H, Hao Y, Zou W, Wu J, Chi Y, Yang J, Hong Y, et al. 2009. Trihydrophobin 1 interacts with PAK1 and regulates ERK/MAPK activation and cell migration. J Biol Chem. 284: 8786-8796.
5. Dennis JW, Granovsky M, Warren CE. 1999. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1473: 21-34.
6. Dennis JW, Laferte S, Waghorne C, Breitman ML, Kerbel RS. 1987. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science. 236: 582-585.
7. Dube DH, Bertozzi CR. 2005. Glycans in cancer and inflammation-Potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4: 477-488.
8. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132: 2557-2576.
9. Gilmore AP. 2005. Anoikis. Cell Death Differ 12 Suppl. 2: 1473-1477.
10. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med. 6: 306-312.
11. Guo HB, Johnson H, Randolph M, Lee I, Pierce M. 2009. Knockdown of GnT-Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. Glycobiology. 19: 547-559.
12. Guo HB, Johnson H, Randolph M, Nagy T, Blalock R, Pierce M. 2010. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci. 107: 21116-211121.
13. Guo HB, Liu F, Zhao JH, Chen HL. 2000. Down-regulation of N-acetylglucosaminyltransferase V by tumorigenesis- or metastasissuppressor gene and its relation to metastatic potential of human hepatocarcinoma cells. J Cell Biochem. 79: 370-385.
14. Guo H, Nairn A, dela Rosa M, Nagy T, Zhao S, Moremen K, Pierce M. 2012. Transcriptional regulation of the protocadherin beta cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. J Biol Chem. 287: 24941-24954.
15. Guo HB, Randolph M, Pierce M. 2007. Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: Inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase. J Biol Chem. 282: 22150-22162.
16. Guo P, Wang QY, Guo HB, Shen ZH, Chen HL. 2004. N-acetylglucos aminyltransferase V modifies the signaling pathway of epidermal growth factor receptor. Cell Mol Life Sci. 61: 1795-1804.
17. Inamori K, Gu J, Ohira M, Kawasaki A, Nakamura Y, Nakagawa T, Kondo A, Miyoshi E, Nakagawara A, Taniguchi N. 2006. High expression of N-acetylglucosaminyltransferase V in favorable neuroblastomas: Involvement of its effect on apoptosis. FEBS Lett. 580: 627-632.
18. Ito Y, Miyoshi E, Sakon M, Takeda T, Noda K, Tsujimoto M, Ito S, Honda H, Takemura F, Wakasa K, et al. 2001. Elevated expression of UDP-N- acetylglucosamine: Alphamannoside beta1, 6 N-acetylglucosaminyltransferase is an early event in hepatocarcinogenesis. Int J Cancer. 91: 631-637.
19. Jiang J, Shen J, Wu J, Wei Y, Chen X, Zong H, Zhang S, Sun M, Xie J, Kong X, et al. 2006. Down-regulation of beta1, 4-galactosyltransferase V is a critical part of etoposide-induced apoptotic process and could be mediated by decreasing Sp1 levels in human glioma cells. Glycobiology. 16: 1045-1051.
20. Lau KS, Dennis JW. 2008. N-Glycans in cancer progression. Glycobiology. 18: 750-760.
21. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW. 2007. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 129: 123-134.
22. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, et al. 2007. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 46: 1426-1435.
23. Liu H, Xu J, Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y, Gu J. 2011. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 71: 7547-7557.
24. Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet. 362: 1907-1917.
25. Lowe JB, Marth JD. 2003. A genetic approach to mammalian glycan function. Ann Rev Biochem. 72: 643-691.
26. Nagaprashantha LD, Vatsyayan R, Lelsani PC, Awasthi S, Singhal SS. 2011. The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer. 128: 743-752.
27. Ohtsubo K, Marth JD. 2006. Glycosylation in cellular mechanisms of health and disease. Cell. 126: 855-867.
28. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW. 2004. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science. 306: 120-124.
29. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z., Irie HY, Gao S, Puigserver P, Brugge JS. 2009. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature. 461: 109-113.
30. Shao DM, Wang QH, Chen C, Shen ZH, Yao M, Zhou XD, Tang ZY, Gu JX. 1999. N-acetylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice. J Exp Clin Cancer Res. 18: 331-335.
31. Soderquist AM, Todderud G, Carpenter G. 1988. The role of carbohydrate as a post-translational modification of the receptor for epidermal growth factor. Adv Exp Med Biol. 231: 569-582.
32. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al. 2010. Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 28: 3994-4005.
33. Weinstein J, Sundaram S, Wang X, Delgado D, Basu R, Stanley P. 1996. A point mutation causes mistargeting of Golgi GlcNAc-TV in the Lec4A Chinese hamster ovary glycosylation mutant. J Biol Chem. 271: 27462-27469.
34. Xu J, Liu H, Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y, Gu J. 2012. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 143: 199-212 e194.
35. Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y, Gu J. 2010. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 52: 142-154.
36. Yanagi M, Aoyagi Y, Suda T, Mita Y, Asakura H. 2001. N-Acetylglucos aminyltransferase Vas a possible aid for the evaluation of tumor invasiveness in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 16: 1282-1289.
37. Yao M, Zhou DP, Jiang SM, Wang QH, Zhou XD, Tang ZY, Gu JX. 1998. Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J Cancer Res Clin Oncol. 124: 27-30.
38. Zhang W, Xu W, Xiong S. 2010. Blockade of Notch1 signaling alleviates murine lupus via blunting macrophage activation and M2b polarization. J Immunol. 184: 6465-6478.
39. Zhang W, Xu W, Xiong S. 2011. Macrophage differentiation and polarization via phosphatidylinositol 3-kinase/Akt-ERK signaling pathway conferred by serum amyloid P component. J Immunol. 187: 1764-1777.